Clinical Evidence on Psilocybin and Its Representation in Media Reporting: A Systematic Review.
Kim Madden, Breanne Flood, Imad Kashir, Rayan Ahmad, Hiba Ali, Rotem Petranker, James MacKillop, Anthony Adili
JAMA Network Open October 1, 2026 DOI: 10.1001/jamanetworkopen.2026.38843 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review Randomized Peer reviewed |
|---|---|
| Population | Published randomized and nonrandomized clinical trials of psilocybin for clinical indications (n=70) and media articles describing clinical use of psilocybin (n=172) |
| Intervention | Psilocybin |
| Topics | Psilocybin |
| Key findings | Trials and media articles both reported positive effects of therapeutic psilocybin at similar frequency (70% of trials reported benefit; 73% of media articles made at least one positive efficacy claim). The authors argue academic publications were more cautious and explicit about methodologic limitations, whereas media reports often presented benefits as established, extrapolated them to indications with little or no trial evidence (e.g., PTSD and anxiety), and provided less safety information (30% of media articles mentioned safety vs. 44% of trials reporting safety outcomes). |
Abstract
Psilocybin has received increased attention as a potential therapeutic intervention, but it is unclear whether news media reporting reflects the strengths and limitations of the clinical trial evidence. To describe the annual counts of published clinical trials of therapeutic psilocybin and contemporaneous media articles and compare tone, efficacy, and safety messaging. This systematic review included English-language randomized and nonrandomized trials of psilocybin for clinical indications published from January 1, 2014, to October 10, 2024, and media articles describing its clinical use published from January 1, 2014, to April 22, 2025. Trials were found by searching Medline, Embase, PsycInfo, and the Cochrane Central Register of Controlled Trials (CENTRAL) and were characterized by design, indication, use of psychotherapy, and reporting of efficacy and safety. Media articles were found through the Factiva database and were characterized by audience, tone, indication, efficacy claim, and safety content. Data were extracted by 2 reviewers. Risk of bias for randomized clinical trials was assessed descriptively using the Cochrane Risk of Bias tool. Annual counts of both published clinical trials (n = 70) and media reports (n = 172) increased from 2018 onward. Depression was the most common clinical indication in trials (47 [67%]) and media articles (138 [80%]), while media articles frequently referenced posttraumatic stress disorder (PTSD) (74 [43%]) and anxiety (72 [42%]) as clinical indications despite absent and limited trial evidence, respectively, for these conditions. Overall, 49 trials (70%) reported benefit for the primary indication; 125 media articles (73%) made at least 1 positive efficacy claim, and 122 (71%) adopted a favorable tone. Trials typically described small sample sizes of less than 100 participants (65 trials [93%]) and methodologic limitations. Overall, 31 trials (44%) reported safety outcomes, with some (24 [34%]) documenting short-term adverse events, such as transient anxiety, nausea, or headache; long-term safety was rarely assessed (4 trials [6%]). Only 51 media articles (30%) mentioned safety; when harms were discussed, potential long-term psychological risks were sometimes noted (12 articles [7%]). In this systematic review of clinical trials and media articles, both reported positive effects of therapeutic psilocybin with similar frequency. Academic publications were more cautious and explicit about methodologic limitations, whereas media reports often presented benefits as established, extrapolated them to indications with little or no trial evidence, and provided less safety information. Clarifying these differences in emphasis may support more transparent public communication of indication-specific evidence and uncertainty as interest in psilocybin-assisted treatments grows.
Comparable studies
Other systematic reviews and meta-analyses on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies Patients with cancer- or illness-related anxiety and depression, major depressive... | 2020 | Systematic review | n = 188 |
| Blinding and expectancy confounds in psychedelic randomized controlled trials | 2021 | Systematic review | |
| Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years Patients from included clinical trials | 2016 | Systematic review | |
| The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis People with elevated symptoms of anxiety and depression | 2020 | Meta-analysis | n = 117 |
| Default Mode Network Modulation by Psychedelics: A Systematic Review Participants from included studies | 2022 | Systematic review |
Citations in the library
Cites 68
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Frontiers in Pharmacology January 17, 2018
and 63 more in the library